This is the second edition of The ‘Shog-A.I. Shimbun’, the AI narrated news report about disability issues in Japan. This episode covers news reports from March 11th – March 14th 2024.
Japan will no longer provide public aid for medical services related to COVID-19 from April, the health ministry officially announced on Tuesday.
After the end of the public aid, patients will be asked to pay 10 to 30 pct of COVID-19 drug costs out of pocket under the country’s health insurance system. Hospitalization subsidies will also be scrapped at the end of this month.
Their Majesties are deeply saddened by the fact that more than 3,000 people have been left behind in isolated villages, some have died due to the disaster, and we are concerned about the deterioration of the health of those evacuated due to the outbreak of infectious diseases. It means that it is being done.
There are concerns that “many residents might die as an indirect result of the earthquake and tsunami because some areas were not receiving adequate food or medicine.”
Mayor Shigeru Sakaguchi of Wajima City, Ishikawa Prefecture, announced on January 7th that one victim of the Noto Peninsula earthquake who had evacuated to an evacuation center in the city had died of hypothermia.
So-called senior cafeterias, where elderly people from the local community gather and dine together, are increasing in Japan amid an increase in elderly people living alone.
The scheme is aimed at preventing social isolation among the elderly and promoting their mental and physical health.
The government adopted an ordinance Friday to abolish the current health insurance cards Dec. 2, 2024, for integration into My Number social security and tax identification cards.
The new issuance of health insurance cards will be terminated on the day. Existing cards within the period of validity will remain usable for up to a year under a one-off measure.
A single course of treatment with an Alzheimer’s drug developed by Japanese company Eisai Co. and U.S. firm Biogen Inc. will cost around 2.98 million yen ($20,500) per year in Japan and will be largely covered by public health insurance, a health ministry body said Wednesday.
As the drug, branded Leqembi, will be covered by public health insurance, those undergoing treatment will pay between 10 to 30 percent of the cost out of their own pocket, depending on their age and income.
A shortage of generic drugs is becoming serious in Japan amid the spread of influenza and the novel coronavirus, prompting the health ministry to make all-out efforts to sort out a structural issue haunting the industry.
Three organizations representing people with disabilities in Aichi Prefecture have submitted a written request to the prefectural government and the city of Nagoya demanding that the government take action in response to the issue of the Megumi Corporation (Tokyo), a welfare company that operates facilities for people with disabilities nationwide, overcharging its users for foodstuffs.
Barrier Free Japan